|Title||Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Flory JH, Small DS, Cassano PA, Brillon DJ, Mushlin AI, Hennessy S|
|Journal||J Comp Eff Res|
|Date Published||2014 Jan|
|Keywords||Administration, Oral, Age Factors, Aged, Body Mass Index, Comparative Effectiveness Research, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin A, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Sex Factors|
AIMS: To provide evidence on the comparative effectiveness of oral diabetes drug combinations.
METHODS: We performed a retrospective, observational cohort study of glycosylated hemoglobin change in outpatients newly exposed to dual- or triple-drug oral diabetes treatment.
RESULTS: Adjusted response to a second drug added to metformin ranged from 0.85 to 1.21% glycosylated hemoglobin decline. Response to a third drug was smaller (0.53-0.91%). Higher baseline glycosylated hemoglobin was associated with larger response; sulfonylurea effectiveness declined over time; and thiazolidinediones were more effective in obese patients and women.
CONCLUSION: Observational data provide results qualitatively consistent with the limited available randomized data on diabetes drug effectiveness, and extend these findings into common clinical scenarios where randomized data are unavailable. Sex and BMI influence the comparative effectiveness of diabetes drug combinations.
|Alternate Journal||J Comp Eff Res|
|PubMed Central ID||PMC3996558|
|Grant List||UL1 RR024996 / RR / NCRR NIH HHS / United States |
UL1 TR000457 / TR / NCATS NIH HHS / United States